BioNTech
NEWS
In addition to coming sooner than expected, the results are even better than expected. The trial hit all primary efficacy endpoints.
There are similarities between the two COVID-19 vaccine candidates, and a few differences. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
The BioNTech scientist said his vaccine can “bash the virus over the head”.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
They caution that as more data is accumulated and analyzed, the efficacy percentage may shift. Nonetheless, it’s extremely promising and there were no serious safety signals.
Several biopharmaceutical companies have made headway as of late in the race to develop a vaccine for COVID-19, which is responsible for the current global pandemic.
Allele Biotechnology and Pharmaceuticals filed lawsuits claiming the companies infringed on Allele’s patented mNeonGreen technology in the development of their COVID-19 treatments.
A few days ago, CNBC reported that five patients, three in Moderna’s and two in Pfizer’s Phase III trials, had experienced more severe, although transient side effects.
JOBS
IN THE PRESS